Purdue University: Eradivir's EV25 Therapeutic Proven to Reduce Advanced-Stage Influenza Viral Loads Faster, More Thoroughly in Preclinical Studies Than Current Therapies
November 20, 2024
November 20, 2024
WEST LAFAYETTE, Indiana, Nov. 20 (TNSres) -- Purdue University issued the following news release:
* * *
Research has been published in Proceedings of the National Academy of Sciences
* * *
Eradivir, a preclinical biotech company, has developed a patent-pending antiviral therapeutic that reduces lung viral loads of advanced-stage influenza in preclinical studies quicker and more effectively than currently available therapies.
A sin . . .
* * *
Research has been published in Proceedings of the National Academy of Sciences
* * *
Eradivir, a preclinical biotech company, has developed a patent-pending antiviral therapeutic that reduces lung viral loads of advanced-stage influenza in preclinical studies quicker and more effectively than currently available therapies.
A sin . . .